Here are three big pharma stocks that Wall Street thinks could soar by at least 30% within the next 12 months. The consensus Wall Street price target for Bristol Myers Squibb (NYSE: BMY) reflects a premium of nearly 34% to the current share price. Of the 22 analysts surveyed by Refinitiv, the most pessimistic of the group thinks that the pharma stock could jump at least 10% higher.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting